NIKKEI 225
26,659.75 +112.70 (+0.42%) HANG SENG
20,602.52 +652.31 (+3.27%) CRUDE OIL
112.60 -1.60 (-1.40%) GOLD FUTURES
1,817.40 +3.40 (+0.19%) DOW
32,626.02 +402.60 (+1.25%) BTC-GBP
23,849.80 -201.19 (-0.84%)
Scholar Rock Holding Corporation (SRRK)
| Previous close | 5.21 |
| Open | 5.39 |
| Bid | 5.86 x 900 |
| Ask | 5.88 x 1100 |
| Day's range | 5.39 - 6.71 |
| 52-week range | 5.11 - 44.95 |
| Volume | |
| Avg. volume | 434,470 |
| Market cap | 200.467M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.41 |
| Earnings date | 07 Mar 2022 - 11 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.40 |
- Business Wire
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
CAMBRIDGE, Mass., May 16, 2022--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
- Zacks
ANI Pharmaceuticals (ANIP) Reports Q1 Loss, Misses Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of -250% and 1.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
CAMBRIDGE, Mass., April 21, 2022--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it is delivering a podium presentation at the 14th European Paediatric Neurology Society (EPNS) Congress, taking place in Glasgow, UK from April 28 - May 2, 2022.
